Upamostat potentiates bortezomib cytotoxicity and delays proteasome recovery in bortezomib-resistant malignant lymphoma cells through modulation of the DDI2/NRF1 axis.
- DOI
- 10.1016/j.bbamcr.2026.120224
- Published
- 2026 Sep 22
- Container
- Biochimica et biophysica acta. Molecular cell research
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/j.bbamcr.2026.120224,
title = {Upamostat potentiates bortezomib cytotoxicity and delays proteasome recovery in bortezomib-resistant malignant lymphoma cells through modulation of the DDI2/NRF1 axis.},
author = {Ota A and Maruyama S and Kudo Y and Kawano S and Saka T and Hayashi R and Yoshino Y and Yamada G and Tsujita T and Takaya D and Fukuzawa K and Honma T and Ikari A and Endo S},
year = {2026},
journal = {Biochimica et biophysica acta. Molecular cell research},
doi = {10.1016/j.bbamcr.2026.120224},
url = {https://doi.org/10.1016/j.bbamcr.2026.120224}
}RIS
TY - JOUR TI - Upamostat potentiates bortezomib cytotoxicity and delays proteasome recovery in bortezomib-resistant malignant lymphoma cells through modulation of the DDI2/NRF1 axis. AU - Ota A AU - Maruyama S AU - Kudo Y AU - Kawano S AU - Saka T AU - Hayashi R AU - Yoshino Y AU - Yamada G AU - Tsujita T AU - Takaya D AU - Fukuzawa K AU - Honma T AU - Ikari A AU - Endo S PY - 2026 JO - Biochimica et biophysica acta. Molecular cell research DO - 10.1016/j.bbamcr.2026.120224 UR - https://doi.org/10.1016/j.bbamcr.2026.120224 ER -
APA
A, O., S, M., Y, K., S, K., T, S., R, H., Y, Y., G, Y., T, T., D, T., K, F., T, H., A, I., & S, E. (2026). Upamostat potentiates bortezomib cytotoxicity and delays proteasome recovery in bortezomib-resistant malignant lymphoma cells through modulation of the DDI2/NRF1 axis.. Biochimica et biophysica acta. Molecular cell research. https://doi.org/10.1016/j.bbamcr.2026.120224
Source records
- pubmed · retrieved 2026-09-25T12:29:09.997Z